Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company is developing a pipeline of products targeted at the therapeutic areas of autoimmune, neutropenia and anemia. On the protein front, Insmed’s product IPLEX is being developed in various stages as a treatment for several medical conditions, with an initial focus on Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) in Italy. Other areas where IPLEX has also shown potential include HIV-associated Adipose Redistribution Syndrome (HARS) and Retinopathy of Prematurity (ROP). IPLEX has United States Food and Drug Administration (FDA) approval. The Company operates an FDA-approved commercial biologics manufacturing facility in Boulder, Colorado.
(Source: 10-K)
